Progesterone receptor loss identifies Luminal B breast cancer subgroups at higher risk of relapse

Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011

(2011) A. Goldhirsch et al.   ANNALS OF ONCOLOGY

Prognostic Value of a Combined Estrogen Receptor, Progesterone Receptor, Ki-67, and Human Epidermal Growth Factor Receptor 2 Immunohistochemical Score and Comparison With the Genomic Health Recurrence Score in Early Breast Cancer

(2011) Jack Cuzick et al.   JOURNAL OF CLINICAL ONCOLOGY

Breast Cancer Subtypes and Response to Docetaxel in Node-Positive Breast Cancer: Use of an Immunohistochemical Definition in the BCIRG 001 Trial

(2009) Judith Hugh et al.   JOURNAL OF CLINICAL ONCOLOGY

Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer

(2009) Maggie C. U. Cheang et al.   JNCI-Journal of the National Cancer Institute

Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial

(2008) M. Untch et al.   ANNALS OF ONCOLOGY

Molecular profiles of progesterone receptor loss in human breast tumors

(2008) Chad J. Creighton et al.   BREAST CANCER RESEARCH AND TREATMENT

Relationship Between Quantitative Estrogen and Progesterone Receptor Expression and Human Epidermal Growth Factor Receptor 2 (HER-2) Status With Recurrence in the Arimidex, Tamoxifen, Alone or in Combination Trial

(2008) Mitch Dowsett et al.   JOURNAL OF CLINICAL ONCOLOGY

Predictive Value of Tumor Ki-67 Expression in Two Randomized Trials of Adjuvant Chemoendocrine Therapy for Node-Negative Breast Cancer

(2008) Giuseppe Viale et al.   JNCI-Journal of the National Cancer Institute